Thomas Powles

Thomas Powles

UNVERIFIED PROFILE

Are you Thomas Powles?   Register this Author

Register author
Thomas Powles

Thomas Powles

Publications by authors named "Thomas Powles"

Are you Thomas Powles?   Register this Author

100Publications

3417Reads

17Profile Views

The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.

Cancer Treat Rev 2020 Jan 11;82:101925. Epub 2019 Nov 11.

PSMAR-IMIM Research Institute in Barcelona and Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.101925DOI Listing
January 2020

Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?

Curr Opin Urol 2020 Jan;30(1):36-40

Specialist Centre For Kidney Cancer, Royal Free Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000696DOI Listing
January 2020

Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.

J Pathol 2019 Oct 24;249(2):151-165. Epub 2019 Jun 24.

Department of Urology, The First Affiliated Hospital and Academy of Medical Sciences, Zhengzhou University, Zhengzhou, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790662PMC
October 2019

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Eur Urol Oncol 2019 Sep 1;2(5):505-514. Epub 2019 Aug 1.

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.06.022DOI Listing
September 2019

Cytoreductive nephrectomy in the current treatment algorithm.

Ther Adv Med Oncol 2019 27;11:1758835919879026. Epub 2019 Sep 27.

Royal Free Hospital, Department of Urology, Renal Cancer Unit, University College London, Division of Surgical and Interventional Sciences, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835919879026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767741PMC
September 2019

Molecular and histopathology directed therapy for advanced bladder cancer.

Nat Rev Urol 2019 08 9;16(8):465-483. Epub 2019 Jul 9.

Department of Oncology, University College London Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0208-0DOI Listing
August 2019

The adjuvant treatment of kidney cancer: a multidisciplinary outlook.

Nat Rev Nephrol 2019 Jul;15(7):423-433

Department of Urology, Netherlands Cancer Institute, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41581-019-0131-xDOI Listing
July 2019

Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.

N Engl J Med 2019 06;380(26):2582

Royal Free NHS Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1905518DOI Listing
June 2019

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

Eur Urol 2019 05 23;75(5):799-810. Epub 2019 Feb 23.

The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.02.011DOI Listing
May 2019

Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition.

Eur Urol Oncol 2019 Apr 9. Epub 2019 Apr 9.

Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.03.001DOI Listing
April 2019

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

Eur Urol 2019 03 28;75(3):435-444. Epub 2018 Sep 28.

Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.09.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697269PMC
March 2019

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 03 16;380(12):1116-1127. Epub 2019 Feb 16.

From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) - all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient Clinic (D.N.), and Hertzen Moscow Cancer Research Institute (B.A.), Moscow; the Christie NHS Foundation Trust, Manchester (R.H.), and Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London (T.P.) - all in the United Kingdom; Centre Hospitalier Universitaire (CHU) de Québec and Université Laval, Quebec, QC (F.P.), and CHU de Montréal, Montreal (D.S.) - both in Canada; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (S.J.A.); Centre Antoine Lacassagne, Université Côte d'Azur, Nice (D.B.), and Hôpitaux Universitaires de Lyon, Lyon (S. Tartas) - both in France; Military Institute of Medicine, Warsaw, Poland (C.S.); Rocky Mountain Cancer Center, Colorado Springs, CO (M.M.); Adelaide and Meath Hospital and University College Dublin, Dublin (R.S.M.); the Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany (J.B.); Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Osaka City University Hospital, Osaka, Japan (S. Tamada); MSD China, Beijing (Q.S.); Merck, Kenilworth, NJ (R.F.P., M.C.); and Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816714DOI Listing
March 2019

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.

Eur Urol 2019 01 13;75(1):100-110. Epub 2018 Oct 13.

The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183075
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.10.010DOI Listing
January 2019

Sunitinib Alone or after Nephrectomy in Renal Cancer.

N Engl J Med 2018 11;379(19):1877-8

Netherlands Cancer Institute, Amsterdam, the Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1811532DOI Listing
November 2018

Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer.

J Clin Oncol 2018 Oct 29:JCO2018792655. Epub 2018 Oct 29.

Thomas Powles, Royal Free Hospital, and Queen Mary University of London, London, United Kingdom; and Brian Rini, Lerner College of Medicine, and Cleveland Clinic, Cleveland, OH.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.79.2655
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.79.2655DOI Listing
October 2018

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Eur Urol Oncol 2018 08 30;1(3):190-198. Epub 2018 May 30.

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.05.002DOI Listing
August 2018

Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.

Clin Genitourin Cancer 2018 04 6;16(2):117-129. Epub 2017 Dec 6.

Bladder Cancer Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878995PMC
April 2018

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

J Clin Oncol 2018 03 8;36(8):765-772. Epub 2018 Jan 8.

Bernard Escudier, Institut Gustave Roussy, Villejuif; Stephane Oudard, Hôpital Européen Georges Pompidou, Paris; Frederic Rolland, Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes, Saint-Herblain, France; Thomas Powles, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University, Columbus, OH; Osvaldo Arén Frontera, Centro Internacional de Estudios Clinicos, Santiago, Chile; Piotr Tomczak, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznań, Poland; Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid, Spain; Leonard J Appleman, University of Pittsburgh Medical Center, Pittsburgh, PA; Harry Drabkin, Medical University of South Carolina, Charleston, SC; Daniel Vaena, University of Iowa Hospitals and Clinics, Iowa City, IA; Steven Milwee, Jillian Youkstetter, and Julie C. Lougheed, Exelixis, Inc., San Francisco, CA; Sergio Bracarda, Ospedale San Donato, Istituto Toscano Tumori (ITT), Arezzo, Italy; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804840PMC
March 2018

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

J Clin Oncol 2018 03 17;36(9):850-858. Epub 2018 Jan 17.

F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA; Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autònoma de Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London, London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.1644DOI Listing
March 2018

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

J Clin Oncol 2018 03 29;36(8):757-764. Epub 2018 Jan 29.

David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Bernard Escudier, Institut Gustave Roussy, Villejuif; Florence Marteau, Ipsen Pharma, Boulogne-Billancourt; Paul Williams, Mapi Group, Lyon, France; Nizar M. Tannir, University of Texas MD Anderson Cancer Center Hospital, Houston; Hans J. Hammers, University of Texas Southwestern Medical Center; Thomas E. Hutson, Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX; Thomas Powles, Queen Mary University of London, London, United Kingdom; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Katriina Peltola, Helsinki University Hospital Cancer Center, Helsinki, Finland; Manuela Schmidinger, Medical University of Vienna, Vienna, Austria; Daniel Y.C. Heng, University of Calgary, Calgary, Alberta, Canada; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; Jae Lyun Lee, University of Ulsan College of Medicine, Seoul, South Korea; Bruce J. Roth, Washington University in St Louis, St Louis, MO; John Baer, Milan Mangeshkar, and Christian Scheffold, Exelixis, South San Francisco; Sumanta Pal, City of Hope National Medical Center, Duarte, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804841PMC
March 2018

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

Eur Urol 2018 02 13;73(2):149-152. Epub 2017 Sep 13.

Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.08.022DOI Listing
February 2018

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

J Clin Oncol 2017 11 30;35(31):3525-3528. Epub 2017 Aug 30.

Torgrim Tandstad, St Olavs University Hospital, Trondheim, Norway; Christian K. Kollmannsberger, University of British Columbia, Vancouver, British Columbia, Canada; Bruce J. Roth, Washington University School of Medicine, St Louis, MO; Claudio Jeldres, Sherbrooke University, Sherbrooke, Quebec, Canada; Silke Gillessen, Kantonsspital, St Gallen, Switzerland; Karim Fizazi, University of Paris Sud, Paris, France; Siamak Daneshmand, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA; William T. Lowrance, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Nasser H. Hanna, Indiana University School of Medicine, Indianapolis, IN; Gabriella Cohn Cedermark, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Darren R. Feldman, Memorial Sloan Kettering Cancer Center and Weill Medical Cornell Medical College, New York, NY; Thomas Powles, Barts Cancer Institute, St Bartholomew's Hospital, Queen Mary University of London, London, United Kingdom; Mark A. Lewis, Intermountain Health, Salt Lake City, UT; Peter Scott Grimison, University of Sydney, Sydney, New South Wales, Australia; Douglas Bank, Testicular Cancer Resource Center, Riverwoods, IL; Christopher Porter, Virginia Mason Medical Center, Seattle, WA; Peter Albers, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; Maria De Santis, Cancer Research Center, University of Warwick, Coventry, United Kingdom; Sandy Srinivas, Stanford University School of Medicine, Stanford, CA; George J. Bosl, Memorial Sloan Kettering Cancer Center, New York, NY; and Craig R. Nichols, Precision Genomics Cancer Research Clinic, Intermountain Health, Salt Lake City, UT; Testicular Cancer Commons, Portland, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.4723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791831PMC
November 2017

Reply to M. Horiguchi et al.

J Clin Oncol 2017 10 11;35(29):3373-3374. Epub 2017 Aug 11.

James Paul, Caroline Kelly, and Jon Stobo, University of Glasgow, Glasgow, United Kingdom; and Thomas Powles, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.4292DOI Listing
October 2017

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

J Clin Oncol 2017 Sep 23;35(26):2993-3001. Epub 2017 Jun 23.

Toni K. Choueiri, Dana-Farber Cancer Institute, Boston; Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, and Humphrey Gardner, AstraZeneca, Waltham, MA; Elizabeth Plimack, Fox Chase Cancer Center, Philadelphia, PA; Eric Jonasch, MD Anderson Cancer Center, Houston, TX; Sumanta Kumar Pal, City of Hope, Duarte, CA; Hendrik-Tobias Arkenau, Sarah Cannon Research Institute, University College London Cancer Institute; Thomas Powles, Barts Cancer Institute, London; Shethah Morgan, AstraZeneca, Cambridge, United Kingdom; Daniel Y.C. Heng, Tom Baker Cancer Center, Calgary, Alberta, Canada; and Laurence Albiges, Institute Gustave Roussy, Paris, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.2967
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.2967DOI Listing
September 2017

Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology.

Authors:
Thomas Powles

Future Oncol 2017 Aug 20;13(18):1581-1583. Epub 2017 Jul 20.

Barts Cancer Center, Barts & The London School of Medicine & Dentistry, Queen Mary University of London.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2017-0207
Publisher Site
http://dx.doi.org/10.2217/fon-2017-0207DOI Listing
August 2017

Clinical Trials Corner.

Authors:
Thomas Powles

Kidney Cancer 2017 Jul 26;1(1):89-91. Epub 2017 Jul 26.

Clinical Professor of Genitourinary Oncology (HCC) The Royal Free NHS Trust and Barts Cancer Institute, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/KCA-179002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179111PMC
July 2017

Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome.

Cell Oncol (Dordr) 2017 Jun 10;40(3):293-297. Epub 2017 Jan 10.

Biobix: Laboratory of Bioinformatics and Computational Genomics, Department of Mathematical Modeling, Statistics and Bioninformatics, Ghent University, Coupure Links 653, 9000, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-016-0313-5DOI Listing
June 2017

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.

J Clin Oncol 2017 Jun 12;35(16):1770-1777. Epub 2017 Apr 12.

Robert J. Jones, Judith Dixon-Hughes, Laura Alexander, Anna Morris, Caroline Kelly, Jon Stobo, and James Paul, University of Glasgow, Glasgow; Syed A. Hussain, University of Liverpool, Liverpool; Andrew S. Protheroe, Churchill Hospital, Oxford; Alison Birtle, Royal Preston Hospital, Preston; Prabir Chakraborti, Royal Derby Hospital, Derby; Robert A. Huddart, Institute of Cancer Research, Sutton; Satinder Jagdev, St James's University Hospital, Leeds; Amit Bahl, Bristol Haematology and Oncology Centre, Bristol; Andrew Stockdale, University Hospital, Coventry; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust, Nottingham; Simon J. Crabb, University of Southampton, Southampton; and Thomas Powles, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7828DOI Listing
June 2017

Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.

Angiogenesis 2017 May 11;20(2):205-215. Epub 2017 Apr 11.

Department of Urology, The Netherlands Cancer Institute, Postbus 90203, 1006 BE, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10456-017-9550-0DOI Listing
May 2017

A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.

Cancer Treat Rev 2017 Mar 2;54:58-67. Epub 2017 Feb 2.

Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.01.007DOI Listing
March 2017

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

J Clin Oncol 2017 Jan 28;35(1):48-55. Epub 2016 Oct 28.

Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.3468DOI Listing
January 2017

Immunotherapy for Renal Cancer: Sequencing and Combinations.

Eur Urol Focus 2016 Dec 20;2(6):582-588. Epub 2017 Apr 20.

Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2017.04.002DOI Listing
December 2016